Board Member
Eton Pharmaceuticals, Inc. (ETON)Equibles does not estimate personal net worth.
Get an email with a short summary when Eton Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ETON alertsSean Brynjelsen is recorded as CEO and Board Member at Eton Pharmaceuticals, Inc. (ETON). The newest filing on record that lists Sean Brynjelsen as CEO and Board Member at Eton Pharmaceuticals, Inc. (ETON) is dated April 24, 2026. The proxy statement of Eton Pharmaceuticals, Inc. reports total compensation of $1,747,045 for Sean Brynjelsen in fiscal 2023, including a base salary of $591,862. Disclosed compensation is on record for 6 fiscal years. Sean Brynjelsen has spoken on 27 earnings calls and 1 other investor event across 1 company, most recently for Eton Pharmaceuticals, Inc. on November 5, 2026. Eton Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Eton Pharmaceuticals, Inc. includes Norbert G. Riedel (Chairman), James Gruber (CFO), Judith Matthews (CFO) and 4 others.
“It was another outstanding quarter for Eaton with record revenue, significant margin expansion, and strong cash flow generation. We continue to fire on all cylinders on both the commercial and development fronts.”
“We had an exceptional second quarter with record revenue, significant margin expansion, and important progress across both our commercial portfolio and pipeline.”
“So let's, we have a, this advances it, I'm assuming? So Eaton Pharmaceuticals was started with the vision of really three main pillars.”
“The first quarter was another great quarter for Eaton. We achieved record product sales, delivering 73% year-over-year product revenue growth. We launched two new major products, Desmota and Hemangio, and we made great strides advancing our R&D programs with the achievement of several development milestones.”
“As you've seen, it's been a very active time at Eden with a number of major developments in the recent weeks and we have some exciting topics to discuss today during the call we'll review fourth quarter results provide additional color on hemangio acquisition and an update on our recent fda approval and commercial…”
Start not stated–present
Last confirmed April 24, 2026
Start not stated–present
Last confirmed April 24, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Eton Pharmaceuticals, Inc. (ETON) | President and Chief Executive Officer | $591,862 | $1,747,045 |
| 2022 | Eton Pharmaceuticals, Inc. (ETON) | President and Chief Executive Officer | $569,541 | $2,119,541 |
| 2021 | Eton Pharmaceuticals, Inc. (ETON) | President and Chief Executive Officer | $542,167 | $2,092,292 |
| 2020 | Eton Pharmaceuticals, Inc. (ETON) | President and Chief Executive Officer | $475,833 | $2,011,293 |
| 2019 | Eton Pharmaceuticals, Inc. (ETON) | President and Chief Executive Officer | $409,958 | $1,946,408 |
| 2018 | Eton Pharmaceuticals, Inc. (ETON) | President and Chief Executive Officer ^^ | $332,313 | $493,022 |
